As chemoresistance is an obstacle in ovarian cancer therapy [1,2], the anti-tumoral effect of DKK3, as well as its synergistic effect with paclitaxel in paclitaxel-resistant ovarian cells, indicates the possibility of a new therapeutic strategy. Here, DKK3 is linked to ovarian cancer.